

E08-04-0426 Bankaitis

LEGENDS TO SUPPLEMENTAL FIGURES.

Supplemental Figure S1. Morphological manifestations of secretory pathway dysfunction in *sec14-1^{ts}* (**A**) and *sec6-4^{ts}* mutants (**B**) were analyzed by thin-section electron microscopy. Yeast were cultured to early logarithmic growth phase in YPD medium at 30°C. The cultures were then shifted to the 37°C for the indicated times. Cells were fixed, embedded in Spurr's resin, stained with uranyl acetate and imaged using a transmission electron microscope (20 kV). Representative images are shown (bar = 2μm). Berkeley bodies (defective TGN/endosomal structures) and undocked secretory vesicles are highlighted by arrows in images of the *sec14-1^{ts}* and *sec6-4^{ts}* mutants, respectively.

Supplemental Figure S2. CPY maturation in *sec14-1^{ts} tlg2Δ* yeast. **(A)** Wildtype, *sec14-1^{ts}*, *tlg2Δ*, and *sec14-1^{ts} tlg2Δ* yeast were grown in minimal media at 30°C, and then shifted to 37°C or maintained at 30°C for 2hrs, and radiolabeled with [³⁵S]-amino acids for 30 min. Chase (0, 15, 30 and 45 min) was initiated by introducing 2mM of both unlabeled methionine and cysteine, and reactions were terminated with ice-cold tricholoroacetic acid (final concentration 5%). CPY was immunoprecipitated with anti-CPY antibodies (1μl/OD600_{nm}). **(B)** Wild-type, *sec14-1^{ts}*, *tlg2Δ*, and *sec14-1^{ts} tlg2Δ* yeast were grown in minimal media at 30°C, and then shifted to 33.5°C or maintained at 30°C for 2hrs, and radiolabeled with [³⁵S]-amino acids for 30 min. Chase (10 min) was initiated by introducing 2mM of both unlabeled methionine and cysteine, and reactions were terminated with ice-cold tricholoroacetic acid (final concentration 5%). CPY was immunoprecipitated with anti-CPY antibodies (1μl/OD600_{nm}). **(C)** Whole cell lysates were prepared from yeast strains of the indicated genotype, resolved by SDS-PAGE and blotted to

nitrocellulose. Blots were probed with either anti-alpha factor or anti-Sec61p polyclonal antibody. Where indicated strains were grown in the presence of 100 μ g/ml tunicamycin (Tm). The ER translocated, signal peptide cleaved, form of alpha-factor (Paf) and the core glycosylated paf modified on each of its three N-linked glycosylation sites (g3 α f) are indicated at right. Wild-type yeast and *sec14-1^{ts}* mutants efficiently mature alpha-factor and those forms are not detectable in the SDS-PAGE system employed. Sec61 (indicated at right) was monitored as normalization control.

Supplemental Figure S3. *sec14-1^{ts} tlg2Δ* yeast possess growth deficiencies consistent with defects in the UPR. **(A)** Wild-type, *sec14-1^{ts}*, *tlg2Δ*, and *sec14-1^{ts} tlg2Δ* yeast were grown overnight at 30°C in either inositol containing (dark grey boxes) or inositol free media (light grey boxes). The A_{600nm} was recorded both before (white boxes) and after growth. **(B)** Wildtype, *sec14-1^{ts}*, *tlg2Δ*, and *sec14-1^{ts} tlg2Δ* yeast were grown overnight at 30°C in synthetic defined media in the absence (dark grey boxes) or presence (light grey boxes) of DTT (4mM). The A_{600nm} was recorded both before (white boxes) and after growth.

Supplemental Figure S4. Hac1^I stability is not compromised in *sec14-1^{ts} tlg2Δ* cells. Wild-type and *sec14-1^{ts} tlg2Δ* yeast harboring a yeast centromeric vector encoding for the expression of the constitutively active HA-Hac1^I mutant were grown in minimal media at 30°C, shifted to 37°C or maintained at 30°C for 2hrs and radiolabeled with [³⁵S]-amino acids for 30 min. HA-Hac1^I was immunoprecipitated with anti-HA antibody **(A)** and the relative amount of HA-Hac1^I isolated from each sample was determined by densitometry **(B)**.

Supplemental Figure S4. Effects of genetic ablation of Isc1 and Ppn1 function on ceramide mass. **(A)** Dihydroceramide and **(B)** phytoceramide mass (fmol ceramide/nmol Pi) are reduced in *sec14-1^{ts} tlg2Δ isc1Δ* and *sec14-1^{ts} tlg2Δ ppn1Δ* yeast relative to *sec14-1^{ts} tlg2Δ* parental cells. Quantitative lipidomics were used to measure endogenous yeast ceramides. Lipids were extracted from 3 pooled cultures (30 OD_{600nm}) of each yeast strain grown overnight at 30°C and shifted to 37°C for 2 hours, prior to lipid extraction.

LEGENDS TO SUPPLEMENTAL TABLES.

Supplemental Table S1 – Plasmids used in this study.


Supplemental Table S2 – A partial listing of genes identified in the *sec14-1^{ts}* SGA screen.

These genes were consistently identified in three independent SGA experiments. The interactions with *arf1Δ*, *spo14Δ*, *sfh3Δ*, and *gcs1Δ* alleles confirm previous studies (see text), whereas the interactions with *snc2Δ*, *gsg1Δ* and *tlg2Δ* alleles are documented here. Otherwise, the listed genetic interactions have not been independently validated by meiotic analyses.




Supplemental Table S3 - (A) The 20 genes with the greatest magnitude of transcriptional down-regulation in *sec14-1^{ts}* *tlg2Δ* mutants relative to wild-type. **(B)** The 20 genes with the greatest magnitude of transcriptional up-regulation in *sec14-1^{ts}* *tlg2Δ* mutants relative to wild-type.

Supplemental Figure S1

(A)




(B)




Supplemental Figure S2


(A)



(B)




(C)




Supplemental Figure S3

(A)




(B)




Supplemental Figure S4



(A)



(B)



Supplemental Figure S5



Supplemental Table S1

<u>Plasmid</u>	<u>Description</u>
pJT30	YCp (<i>UPRE::LACZ, URA3</i>)
pRC43	YCp (<i>HAC1^I, HIS3</i>)
pCTY468	YCp (<i>sec14-1, URA3</i>)
p180	YCp (<i>GCN4::LACZ, URA3</i>)
pCB506	YCp (<i>GFP-SNC1, URA3</i>)
p DsRed-FYVE	YCp (<i>MET3::FYVE-dsRED, HIS3</i>)
pCTY468	YCp (<i>sec14-1, URA3</i>)
pRE853	Cloning intermediate for YIp <i>sec14-1::URA3</i>
pRE860	Cloning intermediate for YIp <i>sec14-1::URA3</i>
pRE861	YIp <i>sec14-1::URA3</i>
pCTY1501	YCp (<i>TLG2, URA3</i>)
pCTY1502	YCp (<i>tlg2^{R13Q}, URA3</i>)
pCTY1503	YCp (<i>tlg2^{Q278R}, URA3</i>)
pCTY1504	YEp (<i>YPC1, URA3</i>)

Supplemental Table S2

sec14^{ts} Synthetic Interactions: Synthetic Genomic Array Results

PROTEIN TRAFFICKING

<u>ORF</u>	<u>Gene</u>	<u>Function</u>
YJL204C	RCY1	Endocytosis
YBR266C	SLM6	Endocytosis
YOR327C	SNC2	V-Snare Exocytosis
YDR108W	GSG1	ER to Golgi Transport (TRAPP Subunit)
YDL192W	ARF1	Exocytosis
YGR261C	APL6	Golgi to Vacuole Transport
YER166W	DNF1	Phospholipid Flippase
YPL051W	ARL3	Endosome to TGN (ARF-Like)
YOL018C	TLG2	Endosome to TGN T-SNARE
YNL154C	YCK2	Casein Kinase I
YLL040C	VPS13/SOI1	TGN Retention
YGL104C	VPS73	Vacuolar Protein Sorting
YPR029C	APL4	Clathrin Adaptor
YOR070C	GYP1	YPT31/32 GAP
YPR051W	MAK3	N-Acetyltransferase (ARL)

CELL WALL BIOGENESIS

<u>ORF</u>	<u>Gene</u>	<u>Function</u>
YNL322C	KRE1	Cell Wall Organization/Biogenesis
YLR436C	ECM30	Cell Wall Organization/Biogenesis
YMR307W	GAS1	Cell Wall Organization/Biogenesis
YGR059W	SPR3	Cell Wall Organization/Biogenesis
YLR371W	ROM2	Cell Wall Organization/Biogenesis
YGR229C	SMI1	Cell Wall Organization/Biogenesis
YOR008C	SLG1	Cell Wall Organization/Biogenesis
YCR089W	FIG2	Cell Wall Organization/Biogenesis

CYTOSKELETON/POLARITY

<u>ORF</u>	<u>Gene</u>	<u>Function</u>
YOR299W	BUD7	Bud Site Selection
YDL151C	BUD30	Bud Site Selection
YOR300W	HUF1	Bud Site Selection
YCR047C	BUD23	Bud Site Selection
YPL161C	BEM4	Bud Site Selection
YLR429W	CRN1	MT Binding/Actin Filament Organization
YDR150W	NUM1	Tubulin Binding/NUC Migration
YNL153C	GIM3	Tubulin Binding/Folding
YML094W	GIM5	Tubulin Binding/Folding
YGR078C	PAC10	Tubulin Binding/Folding

LIPID TRAFFICKING/METABOLISM

<u>ORF</u>	<u>Gene</u>	<u>Function</u>
YER166W	DNF1	Phospholipid Flippase
YKR031C	SPO14	Phospholipase D
YMR015C	ERG5	C-22 Sterol Desaturase
YLR056W	ERG3	C-5 Sterol Desaturase
YLR450W	HMG2	HMG CoA Reductase
YPL057C	SUR1	MIPC Synthase
YBL011W	SCT1	Glycerol-3-P O-Acyltransferase
YNL231C	SFH3	Sec14-Like PITP
YPL087W	YDC1	DI-Hydroceramidase
YLR372W	SUR4/ELO3	Fatty Acid Elongase
YCR034W	FEN1/ELO2	Fatty Acid Elongase
YOR011W	AUS1	MDR-Like Sterol Transporter
YPL069C	BTS1	Farnesyltransferase

Supplemental Table S3

A

Top 20 genes, annotated, up regulated

<i>BTN2</i>	<i>TOS3</i>
<i>SPG1</i>	<i>SMP1</i>
<i>RPN4</i>	<i>CIT2</i>
<i>NRG1</i>	<i>BRR6</i>
<i>ICY2</i>	<i>NCE103</i>
<i>HSP42</i>	<i>ARO10</i>
<i>TIM18</i>	<i>ARL3</i>
<i>OSW1</i>	<i>UPC2</i>
<i>STI1</i>	<i>HSP82</i>
<i>RTS3</i>	<i>TPO4</i>

B

Top 20 genes, annotated, down regulated

<i>VPS20</i>	<i>PHO3</i>
<i>HMRA1</i>	<i>YHB1</i>
<i>COS7</i>	<i>RPL16B</i>
<i>URA3</i>	<i>RPL22A</i>
<i>COS12</i>	<i>RPL20B</i>
<i>ADE17</i>	<i>RPL14A</i>
<i>RPS22A</i>	<i>RPS18B</i>
<i>RPL20A</i>	<i>RPS11A</i>
<i>RPS7A</i>	<i>RPS10A</i>
<i>RPS4A</i>	<i>RPS11B</i>